All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
CD123 is commonly overexpressed in patients with acute myeloid leukemia (AML).1 Pivekimab sunirine is a novel antibody-drug conjugate comprising a high affinity CD123 antibody.1
Here, we summarize the results from a phase I/II dose escalation and dose expansion trial (NCT03386513) investigating the safety and antileukemic activity of pivekimab sunirine in relapsed/refractory AML published by Daver et al.1 in The Lancet Oncology.
Figure 1. A TEAEs Grade ≥3 and B serious TEAEs occurring in ≥5% of patients treated with the RP2D of pivekimab sunirine *
RP2D, recommended phase II dose; TEAE, treatment-emergent adverse event.
*Adapted from Daver, et al.1
Table 1. Efficacy endpoints of patients enrolled in dosing Schedule A and those treated with the RP2D of pivekimab sunirine *
Efficacy endpoint, % (unless otherwise stated) |
Schedule A |
RP2D |
---|---|---|
ORR |
16 |
21 |
Complete remission |
3 |
3 |
Composite complete remission rate |
12 |
17 |
Median duration of ORR, months |
2.0 |
2.6 |
Median duration of composite complete remission, months |
2.2 |
2.3 |
Estimated median OS, months |
2.99 |
5.85 |
ORR, overall response rate; OS, overall survival; RP2D, recommended phase II dose. |
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox